Table 3

Administration of induction chemotherapy
Induction chemotherapy parameter Number of patients (%), N = 18
Dose level
0 12 (67)
-1 6 (33)
DLT 8 (44)
in dose level 0 7 (38)
in dose level -1 1 (6)
Number of doses* of TPF (Median, range) 6, 1 - 6
Number of patients completed maximal level 0 level -1 all patients
number of cycles induction chemotherapy N = 12 N = 6 N = 18
3 cycles 7 (58) 5 (83) 12 (67)
2 cycles 7 (58) 5 (83) 12 (67)
1 cycle** 5 (42) 1 (17) 6 (33)
Dose intensity***, overall (Median, range)
Docetaxel 333.8, 78.2 – 474
Cisplatin 375.3, 78.2 – 474
5-Fluorouracil 10020, 3211 - 11851
Dose density**** per cycle Week 1 Week 2
Dose density, cycle 1 (Median, range)
Docetaxel 72.6, 45.2 – 80.5 71.3, 45 – 80
Cisplatin 73.96, 60.3 – 80.5 73, 45.3 – 80
5-Fluorouracil 3708, 3016 - 4025 3680, 3002 - 4000
Dose density, cycle 2 (Median, range)
Docetaxel 65.9, 45 – 79.2 65.8, 44.8 – 79.2
Cisplatin 70.8, 44.9 – 79.2 71, 44.8 – 79.2
5-Fluorouracil 3572, 2990 - 3960 3550, 2992 – 3960
Dose density, cycle 3 (Median, range)
Docetaxel 66.2, 46.9 – 78.6 60.1, 36.1 – 78.6
Cisplatin 71.3, 44.9 – 78.6 69.5, 45.1 – 78.6
5-Fluorouracil 3546, 2392 - 3931 3482, 2404 - 3931
Number of patients with dose reductions 4 (22)

Oertel et al.

Oertel et al. BMC Cancer 2012 12:483   doi:10.1186/1471-2407-12-483

Open Data